Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GALR1 | P47211 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | PRKCA | P17252 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833669 | 0.89 | TP53 (0.64) | ALOX5TP53MAPTATMSMN1; SMN2 | |
| SCHEMBL3097713 | 0.78 | ALOX5 (0.60) | ALOX5TP53MAPTATMSMN1; SMN2 | |
| SCHEMBL10144997 | 0.78 | ALOX5 (0.60) | ALOX5TP53MAPTATMSMN1; SMN2 | |
| SCHEMBL8698788 | 0.76 | PLOD2 (0.56) | ALOX5MAPTATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL14881542 | 0.74 | ALOX5 (0.56) | ALOX5MAPTATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL14881406 | 0.73 | ALOX5 (0.55) | ALOX5MAPTATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL6499063 | 0.73 | ALOX5 (0.50) | ALOX5MAPTATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL2306348 | 0.73 | ALOX5 (0.58) | ALOX5TP53MAPTATMSMN1; SMN2 | |
| SCHEMBL8698430 | 0.73 | KMO (0.63) | ALOX5MAPTATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL7823334 | 0.73 | ALDH1A1 (0.67) | ALOX5MAPTATMSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442704-B2 | Amide derivatives | ASTRAZENECA AB (SE) | 2008-10-28 | — | — | US | disclosed |
| US-7332483-B2 | 3-(5-benzamido-2-chlorophenyl)-7-methoxy-3,4-dihydroquinazolin-4-one;cytokines (tumor necrosis factor and interleukins) inhibitor; antiinflammatory agent, rheumatoid arthritis, osteoarthritis, psoriasis, chronic obstructive pulmonary disease | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-20060281734-A1 | Amide derivatives | BROWN DEARG S | 2006-12-14 | — | — | US | disclosed |
| US-7008945-B1 | Amide derivatives | ASTRAZENECA AB (SE) | 2006-03-07 | — | — | US | disclosed |
| US-20050245551-A1 | Amide derivatives | ASTRAZENECA AB | 2005-11-03 | — | — | US | disclosed |
| CN-1178932-C | Amide derivatives | — | 2004-12-08 | — | — | CN | disclosed |
| CN-1350530-A | Amide derivatives | ASTRAZENECA AB (SE) | 2002-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245551-A1 | Amide derivatives | IL6, IL6ST, IL1B | ALOX5 481/4885TP53 2400/4885MAPT 4431/4885 |
| US-20060281734-A1 | Amide derivatives | IL6, IL6ST, IL1B | ALOX5 481/4885TP53 2400/4885MAPT 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.